期刊文献+

重组原核表达载体pQE30-HPV58L1的构建及鉴定 被引量:2

CONSTRUCTION AND IDENTIFICATION OF RECOMBINANT PLASMID PQE30-HPV58L1
下载PDF
导出
摘要 目的 :构建重组原核表达载体以获得HPV58L1活性蛋白 ,为进一步研制HPV58基因工程疫苗打下基础。方法 :用聚合酶链反应 (PCR)扩增HPV58L1完整编码区基因 ,将PCR扩增产物克隆至 pUC1 9质粒中并测序。利用 pQE30质粒载体构建重组原核表达载体 pQE30 HPV58L1 ,并通过酶切电泳验证重组结果的正确性。结果 :PCR扩增出 1 6Kb特异性片段 ,经克隆至pUC1 9后测序表明序列同源性与Gen Bank报道一致。重组质粒 pQE30 HPV58L1酶切后显示其大小约 5 1Kb ,酶切图谱与预期相同。 结论 :成功构建了重组原核表达载体 pQE30 HPV58L1。 Objective:To construct a recombinant prokaryotic expression vector pQ30 HPV58L1 for obtaining the HPV58 L1 protein expressed in E coli and developing the genetic engineering vaccine.Methods:The full length L1 coden region of HPV58 was amplified by PCR,and cloned into pUC19,sequenced.The recombinant expression vector pQE30 HPV58L1 was then constructed by inserting the HPV58 L1 gene into pQE30.Restriction analysis was used to confirm the exact ligation of pQE30 HPV58L1 Results:A 1 600 bp DNA fragment was amplified with PCR.Recombinant plasmid pUC19 HPV58L1 and pQE30 HPV58L1 were constructed and sequence analysis revealed the same homology to published data in GenBank.Restriction analyses of pQE30 HPV58L1 were consistent with the theoretically predicted results.Conclusion:We successfully constructed the recombinant prokaryotic expression vector pQE30 HPV58L1
出处 《中国微生态学杂志》 CAS CSCD 2003年第1期24-25,共2页 Chinese Journal of Microecology
关键词 人乳头瘤病毒58型 L1基因 基因重组 Human papillomavirus type 58 L1 gene Recombination
  • 相关文献

参考文献2

二级参考文献7

  • 1林玉纯,李洁.我国人乳头瘤病毒16型及一新型的分子克隆及鉴定[J].中华实验和临床病毒学杂志,1993,7(1):19-25. 被引量:3
  • 2李洁,中华实验和临床病毒学杂志,1994年,8卷,4期,326页
  • 3林玉纯,中华肿瘤杂志,1988年,3卷,10期,196页
  • 4章文华,中华肿瘤杂志,1987年,9卷,6期,433页
  • 5团体著者,中华人民共和国恶性肿瘤地图集,1979年
  • 6李洁,1994年
  • 7林玉纯,中华肿瘤杂志,1988年,3卷,10期,204页

共引文献79

同被引文献23

  • 1刘宝印,李洁,De,李力,龚林,王宏,杨学志,林玉纯.我国人乳头瘤病毒58型感染与宫颈癌的关系[J].中华实验和临床病毒学杂志,1996,10(2):118-121. 被引量:15
  • 2Hagensee M E, Olson N H, Baker T S et al. Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids [J]. J Virol, 1994;68(7) :4503-4505.
  • 3Schiller J T. Papillomavirus-like particle vaccines for cervical cancer [J]. Mol Med Today, 1999;5(5) :209-215.
  • 4Carter J J, Koutsky L A, Hughes J P et al. Comparison of human papillomavirus types 16,18 and 6 capsid antibody responses following incident infection [J]. J Infect Dis,2000; 181 (6): 1911-1919.
  • 5Wang Z, Christensen N, Schiller J T et al. A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera [J] .J Gen Virol, 1997;78(9) :2209-2215.
  • 6Crawford L V, Crawford E M. A comparative study of polyma and papillomavirus [J]. Virology,1963;21(3) :258-263.
  • 7Kirij Y, Iwamoto S, Matsukura T. Human papillomavirus type 58 DNA sequence [J]. Virology, 1991;185(1):424-427.
  • 8Walboomers J M, Jacobs M V, Manos M M et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide [J] .J Pathol,1999; 189(1): 12-19.
  • 9De Villiers E M. Papillomavirus and HPV typing [ J]. Clin Dermatol,1997; 15(2): 199-206.
  • 10Chan P K, Li W H, Chan M Y et al. High prevalence of human papillomavirus type 58 in Chinese women with cervical cancer and precancerous lesions [J]. J Med Virol, 1999;59(2) :232-238.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部